Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, several of in-clinic treatment centers have announced they are closing their operations.
One of them is the famed Field Trip Health & Wellness Ltd. (OTC:FTHWF) which, "in an effort to reduce expenditures and preserve capital" will close its facilities in Chicago, Washington DC, Seattle, San Diego and Fredericton, Canada as of April 15, 2023.
Interestingly, not long ago a conference hosted by Cantor Fitzgerald analyst Pablo Zuanic, Chad ketamine therapy companies Field Trip, Irwin Naturals (OTC:IWINF) and Numinus Wellness (OTC:NUMIF) shared their views on the ketamine space, Irwin's CEO praised the value of Field Trip's offer.
Field Trip will provide clients with information on finding alternative care providers, how to access their medical records and other information required by applicable laws and regulations.
Moreover, the company's Independent Committee (IC) created last December to assess strategic options, along with financial and legal advisors, will "continue to review operations and investigate alternate courses of actions including, but not limited to, further cost reductions, restructuring, the potential sublease or closure of clinic locations and settlement of lease obligations."
See also: Field Trip H&W Closes Q3 2023 On Material Uncertainty, Need To Lower Costs & Adapt To New Regulations
Another major provider has also announced it will be shutting down its ketamine therapy clinic. Delic Holdings (OTC:DELCF)' acquired Ketamine Wellness Centers (KWC) have "suspended" their operations. While providing their patients the chance to obtain their records, no further public information was made available at the moment.
Although many ketamine therapy businesses are still thriving as patients treat their depression, anxiety, or other mental health conditions and PTSD, the almost concurrent announcements indicate that this might be more than a mere coincidence. Business, as we know, requires a wait-and-see (or in this case, inform) approach.
The second edition of the Benzinga Psychedelics Capital Conference is coming your way! The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.
Get your tickets now before prices go up!
Photo: Benzinga edit with photo by woraatep suppavas on Shutterstock and Doc James on Wikimedia Commons.
緊隨著包括氯胺酮療法在內的遠端醫療新規定的宣佈，幾家診所治療中心已經宣佈關閉他們的業務。
其中之一是著名的野外旅行健康與健康有限公司(場外交易代碼：FTHWF)，該公司將於2023年4月15日起關閉其在芝加哥、華盛頓特區、西雅圖、聖地亞哥和加拿大弗雷德裡克頓的設施。
有趣的是，不久前由Cantor Fitzgerald分析師Pablo Zuanic、乍得氯胺酮治療公司field Trip、Irwin Naturals(場外交易代碼：IWINF)和Nnuus Wellness(場外交易代碼：NUMIF)主辦的一次會議分享了他們對氯胺酮領域的看法，Irwin的首席執行官稱讚了field Trip的報價的價值。
實地考察旅行將向客戶提供有關尋找替代護理提供者、如何獲取他們的醫療記錄以及適用法律和法規要求的其他資訊的資訊。
此外，該公司去年12月成立的獨立委員會(IC)將與財務和法律顧問一起評估戰略選擇，將“繼續審查運營並調查替代行動方案，包括但不限於進一步降低成本、重組、可能轉租或關閉診所地點以及清償租賃義務。”
另請參閱：實地考察H&W因材料不確定性而結束2023年第三季度，需要降低成本並適應新法規
另一家主要供應商也宣佈將關閉其氯胺酮治療診所。Delic Holdings(場外交易代碼：DELCF)收購的氯胺酮健康中心(KWC)已經“暫停”運營。雖然他們的病人有機會獲得他們的記錄，但目前沒有進一步的公開資訊。
儘管許多氯胺酮治療業務仍在蓬勃發展，因為患者正在治療他們的抑鬱、焦慮或其他精神健康狀況和創傷後應激障礙，但幾乎同時宣佈的消息表明，這可能不僅僅是巧合。正如我們所知，商業需要一種觀望(或在這種情況下，通知)的方式。
T他本辛加迷幻藥資本會議第二版正在向你走來！活動將於2023年4月13日在佛羅裡達州的楓丹白露邁阿密海灘酒店舉行。這裡是達成交易、籌集資金、啟動並購、會見投資者和關鍵合作夥伴的地方。
現在就去買票吧在物價上漲之前！
圖片：Benzinga在Shutterstock上由woraatep suppaas編輯，Doc James在維基媒體上編輯。
